Processing...
Clinical Trials for Small Cell Lung Cancer
Search
Search
There are 425 active trials for advanced/metastatic small cell lung cancer.
Click on a trial to see more information.
425 trials meet filter criteria.
Sort by:
TrialFetch AI summary: Adults with advanced or metastatic non-small cell lung cancer harboring EGFR activating mutations who have progressed on or are ineligible for standard EGFR-TKI therapies (including cases with resistance mutations like C797S) may enroll to receive BG-60366, an oral chimeric degradation activation compound that selectively degrades mutant EGFR. Prior small cell transformation, symptomatic CNS metastases, previous fourth-generation EGFR-TKIs, and significant interstitial lung disease are exclusion criteria.
ClinicalTrials.gov ID: NCT06685718
TrialFetch AI summary: This trial enrolls adults with advanced or metastatic GPC3-expressing solid tumors (including hepatocellular carcinoma, AFP-producing gastric cancer, extragonadal yolk sac tumors, non-dysgerminomas, or GPC3-positive squamous NSCLC) who have ECOG 0-1. Patients will receive the investigational bispecific antibody BGB-B2033 (targeting GPC3 and 4-1BB) alone or combined with the anti-PD-1 antibody tislelizumab.
ClinicalTrials.gov ID: NCT06427941
TrialFetch AI summary: This trial enrolls adults with recurrent, unresectable, locally advanced, or metastatic solid tumors—including colorectal, pancreatic, NSCLC, ovarian cancer, mesothelioma, and others—that express mesothelin (MSLN) and have lost HLA-A*02 expression, who are heterozygous for HLA-A*02. Eligible patients receive a single infusion of A2B694, an autologous CAR T-cell therapy engineered with a logic-gated Tmod system to selectively target MSLN-positive, HLA-A*02-negative tumor cells.
ClinicalTrials.gov ID: NCT06051695
TrialFetch AI summary: Eligible patients are adults with metastatic or advanced solid tumors—including breast, non-small cell lung (EGFR-mutant or wild-type), gastric, gastroesophageal, or colorectal cancer—who have progressed on, are intolerant to, or lack access to standard therapies. The investigational treatment is DM001, a bispecific antibody-drug conjugate targeting TROP2 and EGFR and delivering a topoisomerase I inhibitor, administered intravenously every 21 days.
ClinicalTrials.gov ID: NCT06475937
TrialFetch AI summary: This study enrolls adults with locally advanced unresectable or metastatic solid tumors harboring KRAS G12C mutations who have progressed on or are intolerant to standard therapy, to receive oral FMC-376, a novel dual inhibitor of both active and inactive KRAS G12C. Eligible patients must have ECOG 0-1.
ClinicalTrials.gov ID: NCT06244771
TrialFetch AI summary: This trial enrolls adults with metastatic, measurable solid tumors (including GI, GU, breast, ovarian, endocrine tumors, NSCLC, and multiple myeloma with plasmacytomas) who have progressed after standard therapies, and treats them with autologous T-cells genetically engineered to express T-cell receptors targeting patient-specific tumor neoantigens, following lymphodepletion, with or without the addition of pembrolizumab. The investigational TCR therapy directly targets mutated or viral antigens unique to each patient’s cancer in an effort to induce durable tumor regression.
ClinicalTrials.gov ID: NCT03412877
TrialFetch AI summary: Eligible patients are adults with locally advanced or metastatic NSCLC harboring EGFR ex19del or L858R mutations who have developed C797X-mediated resistance after prior third-generation EGFR TKI (e.g., osimertinib) therapy; participants receive STX-241, an oral, CNS-penetrant, fourth-generation EGFR inhibitor specifically designed to overcome C797X resistance.
ClinicalTrials.gov ID: NCT06567015
TrialFetch AI summary: This trial enrolls adults with advanced or metastatic ER+ HER2- breast cancer, mCRPC, or NSCLC who have progressed after standard therapies, to receive OP-3136, an oral selective KAT6A/B inhibitor targeting key epigenetic regulators, as monotherapy. Eligible patients must have unresectable disease or no further effective standard treatment options.
ClinicalTrials.gov ID: NCT06784193
TrialFetch AI summary: Adults with unresectable/metastatic solid tumors harboring KRAS G12D and HLA-C*08:02 (e.g., NSCLC, colorectal, pancreatic, endometrial) after ≥1 prior therapy receive lymphodepletion followed by a single infusion of NT-112, an autologous TCR-engineered T-cell therapy targeting KRAS G12D and CRISPR-edited to disrupt TGF-βRII, with IL-2 support. Single-arm dose escalation assessing safety and preliminary efficacy.
ClinicalTrials.gov ID: NCT06218914
TrialFetch AI summary: This trial enrolls adults with unresectable, locally advanced or metastatic solid tumors—including a wide range such as head and neck, lung, bladder, prostate, breast, colorectal, and others—who have progressed on or are intolerant to standard therapies. Patients receive MGC026, a B7-H3-targeted antibody-drug conjugate delivering a topoisomerase I inhibitor (exatecan), with cohorts in both dose escalation and expansion phases.
ClinicalTrials.gov ID: NCT06242470